Universal 'Off-the-Shelf' cell therapy tested for Tough-to-Treat leukemia
NCT ID NCT07432100
Summary
This early-stage study is testing a new type of cell therapy called 'universal' CLL1 CAR-T for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses genetically modified immune cells designed to find and attack leukemia cells. The main goals are to see if the treatment is safe, how well it works to reduce leukemia in the bone marrow, and how long patients live without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.